YB-1 binds the 3' splice site of EGFR exon 3in glioblastoma cells, but a YB-1 decoycannot act on EGFR alone

RNA oligonucleotides directed at a splice site can suppress a gene without touching its protein, and a companion preprint reports that oligonucleotides against the 3' splice site of EGFR exon 3 reduce proliferation of A172 glioblastoma cells. That work rests on a SpliceAid prediction of a Y-box binding protein 1 (YB-1, YBX1) site at the targeted sequence, which has never been tested. This study tests three premises of that design against deposited CLIP, RIP, knockdown RNA-seq and splice-junction data. First, whether exon 3 is a defensible target among the 26 internal exons of EGFR. Applying four criteria in sequence - encoding sequence upstream of the kinase domain, frameshifting when skipped, lying within the first 200 codons, and carrying the YB-1 CA(U/C)C core at its 3' splice site - leaves exactly one exon, exon 3. The frameshift requirement is not cosmetic: EGFRvIII, the in-frame deletion of exons 2 to 7 (801 nt, 267 codons), is constitutively active, so inducing an in-frame skip in EGFR risks producing a signalling-competent receptor. Second, whether YB-1 binds there. A deposited YBX1 eCLIP peak from U251 glioblastoma cells (GSE213046) maps to chr7:55,143,305-55,143,308, the first four nucleotides of exon 3, immediately 3' of the splice acceptor AG (p = 1.3 x 10^-3, log2FC = 3.29). Six YBX1 CLIP datasets from non-glial cells also detect EGFR binding, but not at this position: across the four with mapped site coordinates, none of 103 sites overlaps exon 2, intron 2 or exon 3, and exonic binding is concentrated in exon 28, the 3'UTR. The U251 dataset differs in that its two most 5' exonic peaks lie in exon 1 and in exon 3. Third, whether a decoy carrying the YB-1 consensus can act specifically on EGFR. It cannot. In U251, YB-1 binding sites fall in 8,801 genes, 7,840 of which are expressed there - 42.8% of the expressed transcriptome - and the CA(U/C)C core occurs 48 times in the EGFR mRNA alone. Across four glioblastoma YBX1-knockdown RNA-seq datasets, EGFR mRNA changes by |log2FC| 0.23 to 0.59 and rises in three of the four, ranking 2,418th to 16,274th by effect size. Public U2AF65 iCLIP adds a constraint on mechanism. The 30 nt upstream of the exon 3 acceptor carry 92 crosslinks in pooled HeLa data, ranking tenth among the 26 internal exons of EGFR, whereas the CD44 variable exon v5 tract, on which the YB-1/U2AF65 mechanism was established, carries 15. The EGFR tract is not short of U2AF65, and the two proteins do not share it: the U2AF65 footprint runs from -21 to -3 while the YB-1 peak sits at +1 to +4, across the acceptor and inside the exon. The route by which YB-1 is known to act at a 3' splice site therefore does not obviously apply here. Separately, skipping of exon 3 shifts the reading frame and generates a premature stop 2,771 nt upstream of the final exon junction, making the transcript a canonical nonsense-mediated decay substrate. Across 43 public RNA-seq samples the skipping junction carried 4 reads against approximately 1,836 inclusion reads (PSI ~ 0.998), all 4 in a glioblastoma line. Together these results support YB-1 contact at the exon 3 3' splice site in glioblastoma specifically, provide a reproducible rationale for that target, and set a quantitative bound on what a YB-1 decoy can be claimed to do.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11720196/v1
Primary Topic
RNA Research and Splicing
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

YB-1 binds the 3' splice site of EGFR exon 3in glioblastoma cells, but a YB-1 decoycannot act on EGFR alone

Kenji Ohe, Kyungseung Kwon
Research Square
RNA Research and Splicing
preprint

YB-1 binds the 3' splice site of EGFR exon 3in glioblastoma cells, but a YB-1 decoycannot act on EGFR alone

Kenji Ohe, Kyungseung Kwon
preprint en

Abstract

RNA oligonucleotides directed at a splice site can suppress a gene without touching its protein, and a companion preprint reports that oligonucleotides against the 3' splice site of EGFR exon 3 reduce proliferation of A172 glioblastoma cells. That work rests on a SpliceAid prediction of a Y-box binding protein 1 (YB-1, YBX1) site at the targeted sequence, which has never been tested. This study tests three premises of that design against deposited CLIP, RIP, knockdown RNA-seq and splice-junction data. First, whether exon 3 is a defensible target among the 26 internal exons of EGFR. Applying four criteria in sequence - encoding sequence upstream of the kinase domain, frameshifting when skipped, lying within the first 200 codons, and carrying the YB-1 CA(U/C)C core at its 3' splice site - leaves exactly one exon, exon 3. The frameshift requirement is not cosmetic: EGFRvIII, the in-frame deletion of exons 2 to 7 (801 nt, 267 codons), is constitutively active, so inducing an in-frame skip in EGFR risks producing a signalling-competent receptor. Second, whether YB-1 binds there. A deposited YBX1 eCLIP peak from U251 glioblastoma cells (GSE213046) maps to chr7:55,143,305-55,143,308, the first four nucleotides of exon 3, immediately 3' of the splice acceptor AG (p = 1.3 x 10^-3, log2FC = 3.29). Six YBX1 CLIP datasets from non-glial cells also detect EGFR binding, but not at this position: across the four with mapped site coordinates, none of 103 sites overlaps exon 2, intron 2 or exon 3, and exonic binding is concentrated in exon 28, the 3'UTR. The U251 dataset differs in that its two most 5' exonic peaks lie in exon 1 and in exon 3. Third, whether a decoy carrying the YB-1 consensus can act specifically on EGFR. It cannot. In U251, YB-1 binding sites fall in 8,801 genes, 7,840 of which are expressed there - 42.8% of the expressed transcriptome - and the CA(U/C)C core occurs 48 times in the EGFR mRNA alone. Across four glioblastoma YBX1-knockdown RNA-seq datasets, EGFR mRNA changes by |log2FC| 0.23 to 0.59 and rises in three of the four, ranking 2,418th to 16,274th by effect size. Public U2AF65 iCLIP adds a constraint on mechanism. The 30 nt upstream of the exon 3 acceptor carry 92 crosslinks in pooled HeLa data, ranking tenth among the 26 internal exons of EGFR, whereas the CD44 variable exon v5 tract, on which the YB-1/U2AF65 mechanism was established, carries 15. The EGFR tract is not short of U2AF65, and the two proteins do not share it: the U2AF65 footprint runs from -21 to -3 while the YB-1 peak sits at +1 to +4, across the acceptor and inside the exon. The route by which YB-1 is known to act at a 3' splice site therefore does not obviously apply here. Separately, skipping of exon 3 shifts the reading frame and generates a premature stop 2,771 nt upstream of the final exon junction, making the transcript a canonical nonsense-mediated decay substrate. Across 43 public RNA-seq samples the skipping junction carried 4 reads against approximately 1,836 inclusion reads (PSI ~ 0.998), all 4 in a glioblastoma line. Together these results support YB-1 contact at the exon 3 3' splice site in glioblastoma specifically, provide a reproducible rationale for that target, and set a quantitative bound on what a YB-1 decoy can be claimed to do.

Research Square
Fukuoka University (JP)
RNA Research and Splicing
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon